Amy Ruzicka, OD, FAAO, will be filling in for me this week. Read more about her below.

YOUR RUNDOWN

New topline results are in from the phase 3 trial of Beovu.

The first interpretable results of the phase 3 KITE study assessing the efficacy and safety of brolucizumab 6 mg (Beovu, Novartis) in patients with diabetic macular edema (DME) were recently reported.

Tell me about the study.

The KITE pivotal trial is an ongoing 2-year study that enrolled 360 patients with DME across 80 centers in 23 countries.

What did they find?

The trial met its primary and key secondary endpoints, demonstrating noninferiority for Beovu versus aflibercept 2 mg (Eylea, Regeneron) in mean change in BCVA at year one (week 52). In a secondary endpoint, Beovu demonstrated superior improvement compared with Eylea in change of central subfield thickness over the period of weeks 40 through 52. More than half of the patients in the Beovu arm were maintained on a 3-month dosing interval through year one, following the loading phase. All patients in the Eylea arm were on a 2-month dosing interval after the loading phase.

The take home:

Beovu demonstrated an overall well-tolerated safety profile comparable to Eylea. Additionally, the rate of intraocular inflammation was equal between both drugs. Novartis is conducting a second study in DME and anticipates results later in the year. (via)


WHAT YOUR PATIENT MIGHT ASK YOU

Can issues with my eyes be causing my headaches?

Although diseases of the eye are one of the least common causes of headaches, vision changes and headaches can be a symptom of some serious eye problems, including angle-closure glaucoma and giant cell arteritis.

With digital device use on the rise, a more likely eye-related cause of headache and blurry vision is eye strain. Advise patients to rest their eyes using the 20-20-20 rule: every 20 minutes look at an object at least 20 feet away for at least 20 seconds. Other ways to prevent eye strain include wearing blue light-blocking glasses, reducing computer monitor contrast and brightness, reducing computer screen glare, positioning the computer screen 24 to 26 inches away and slightly lower than eye level, and enabling night mode on digital devices. (via) (via)


ABOUT THE GUEST WRITER

Dr. Ruzicka, also known as Dr. Amy or EyeBuzz

Amy Ruzicka, OD, FAAO, spends her weekdays at the Bascom Palmer Eye Institute and weekends at home with her two fur babies and husband. She stays active in the profession by mentoring young optometrists through the National Optometric Association mentorship program, posting weekly eye buzz facts on Instagram (@eyebuzz2020), and promoting a sustainable healthy lifestyle.

Have a great week!